Short answer
Oncology Institute, Inc. (TOI) filed an 8-K current report with the SEC on August 21, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). $25 million revolving credit facility, providing working-capital flexibility through August 20, 2029.
Oncology Institute, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $25 million revolving credit facility, providing working-capital flexibility through August 20, 2029
- $4.75 million outstanding at closing, secured by substantially all SOM, LLC collateral
- Borrowing-base availability tied to accounts receivable, with lockbox controls over specified professional corporations
- Interest at Term SOFR plus 3.95%, with Term SOFR floor of 2.00% and 5.00% default-rate premium
- Minimum-use and termination fees increase financing costs, while covenants restrict additional debt, distributions, investments and liens
Item 2.03 · Creation of a Direct Financial Obligation
- Item 2.03 incorporates Item 1.01, indicating a newly created direct financial obligation or off-balance-sheet arrangement
- Obligation terms, amount, maturity, interest rate and intended use require review of Item 1.01 or its exhibit
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Oncology Institute, Inc. 8-K filings
Get the next TOI 8-K as it lands
Follow TOI for push alerts, or ask the research agent what this filing means.